Envestnet Asset Management
TXG icon

Envestnet Asset Management’s 10x Genomics TXG Stock Holding History

Envestnet Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.04M Sell
79,314
-29,318
-27% -$768K ﹤0.01% 2840
2026
Q1 		$2.31M Buy
108,632
+46,819
+76% +$936K ﹤0.01% 2911
2025
Q4 		$1.01M Sell
61,813
-32,183
-34% -$486K ﹤0.01% 3258
2025
Q3 		$1.1M Sell
93,996
-876
-0.9% -$11.4K ﹤0.01% 3275
2025
Q2 		$1.1M Sell
94,872
-829
-0.9% -$7.56K ﹤0.01% 3232
2025
Q1 		$835K Buy
95,701
+12,136
+15% +$153K ﹤0.01% 3316
2024
Q4 		$1.2M Sell
83,565
-22,189
-21% -$350K ﹤0.01% 3042
2024
Q3 		$2.39M Buy
105,754
+49,111
+87% +$1.02M ﹤0.01% 2536
2024
Q2 		$1.1M Buy
56,643
+13,449
+31% +$352K ﹤0.01% 2968
2024
Q1 		$1.62M Buy
43,194
+21,099
+95% +$927K ﹤0.01% 2704
2023
Q4 		$1.24M Buy
22,095
+9,335
+73% +$406K ﹤0.01% 2782
2023
Q3 		$526K Buy
12,760
+5,860
+85% +$305K ﹤0.01% 3220
2023
Q2 		$385K Sell
6,900
-157
-2% -$8.5K ﹤0.01% 3355
2023
Q1 		$394K Sell
7,057
-5,630
-44% -$263K ﹤0.01% 3305
2022
Q4 		$462K Sell
12,687
-582
-4% -$19K ﹤0.01% 3134
2022
Q3 		$378K Sell
13,269
-2,461
-16% -$93.8K ﹤0.01% 3213
2022
Q2 		$712K Buy
15,730
+1,866
+13% +$96.8K ﹤0.01% 2847
2022
Q1 		$1.05M Sell
13,864
-1,267
-8% -$111K ﹤0.01% 2620
2021
Q4 		$2.25M Buy
15,131
+4,510
+42% +$691K ﹤0.01% 2084
2021
Q3 		$1.55M Buy
10,621
+4,623
+77% +$794K ﹤0.01% 2260
2021
Q2 		$1.18M Buy
5,998
+2,106
+54% +$381K ﹤0.01% 2409
2021
Q1 		$704K Buy
3,892
+740
+23% +$128K ﹤0.01% 2645
2020
Q4 		$446K Buy
3,152
+1,255
+66% +$182K ﹤0.01% 2717
2020
Q3 		$237K Buy
+1,897
New +$199K ﹤0.01% 2831

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management's TXG Position: Q2 2026 in Review

Envestnet Asset Management reduced its 10x Genomics (TXG) stake by 27% in Q2 2026, selling an estimated $768K and leaving 79,314 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Envestnet Asset Management first reported a position in TXG in Q3 2020 and has held it in 24 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Envestnet Asset Management held 79,314 shares of 10x Genomics worth $3.04M as of Q2 2026.
  • Envestnet Asset Management sold 29,318 10x Genomics shares in Q2 2026, an estimated $768K.
  • 10x Genomics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2840 holding.
  • Envestnet Asset Management first reported a position in 10x Genomics in Q3 2020 and has held it in 24 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.